Fosamax for Male Osteoporosis: Insurance Coverage and Real Cost Breakdown

Why You Might Be Reading This as a Woman

You may be here because your partner, father, or son was prescribed Fosamax and you are the one researching whether insurance will cover it. Or you may be a woman in perimenopause or postmenopause who has seen alendronate recommended for bone protection and wants to understand the drug more fully, including the parts of its story that involve men.

Either way, this article covers the off-label use of alendronate in men with osteoporosis, what insurance typically does and does not pay for, what you will actually spend out of pocket, and how the clinical picture differs between men and women. Alendronate's evidence base was built mostly in women. That context matters when you are weighing it for anyone.

What "Off-Label" Means Here and Why It Matters for Insurance

Alendronate received FDA approval specifically for osteoporosis in postmenopausal women, for glucocorticoid-induced osteoporosis in men and women, and for Paget's disease. Its use for primary osteoporosis in men is off-label.

Off-label prescribing is legal and common in the United States. However, insurers often treat off-label use as grounds for denial or for requiring prior authorization, regardless of the strength of the clinical evidence. A 2020 analysis published in JAMA Internal Medicine found that off-label drug use accounts for roughly 20 percent of all prescriptions in the United States, yet coverage denial rates for off-label indications can be substantially higher than for approved indications.

For alendronate in men specifically, the Endocrine Society's 2012 clinical practice guideline on male osteoporosis explicitly recommends alendronate as a first-line pharmacologic treatment, and the American College of Physicians recommends bisphosphonates for men with osteoporosis based on evidence of fracture reduction. That guideline support does not automatically translate into insurer coverage, but it gives your prescriber strong ammunition for a prior authorization appeal.

How Insurers Classify the Indication

Most commercial insurers, Medicare, and Medicaid follow their own formulary criteria. For alendronate in a male patient, the insurer's pharmacy benefit team will typically ask:

• Does the patient have a T-score of -2.5 or lower at the spine, hip, or femoral neck, confirmed by DXA?
• Has an underlying secondary cause (hypogonadism, glucocorticoid use, malabsorption) been ruled out or documented?
• Has a first-line FDA-approved therapy for men been tried, such as zoledronic acid or risedronate, both of which carry FDA approval for male osteoporosis?

If the prescriber documents a T-score below -2.5 and a clinical rationale, approval rates for prior authorization improve significantly. Keep copies of every DXA report.

Medicare Part D Specifics

Medicare Part D covers alendronate for postmenopausal osteoporosis and glucocorticoid-induced osteoporosis. Coverage for primary male osteoporosis under Part D is plan-dependent. Generic alendronate (70 mg weekly) appears on most Part D formularies as a Tier 1 or Tier 2 drug, meaning a low copay applies when the covered indication is documented. When the indication is off-label for a male patient, some plans will cover it anyway at the formulary tier because the drug itself is approved; others may require a step-therapy requirement showing a prior approved male-osteoporosis agent.

The Real Cost of Alendronate Without Insurance

Generic alendronate 70 mg (one tablet per week, four tablets per month) is one of the least expensive osteoporosis medications available. GoodRx pricing data consistently shows the monthly cost ranging from approximately $4 at discount pharmacies to $15 at standard retail chain pharmacies for the generic formulation.

Brand-name Fosamax is rarely dispensed anymore. When it is, the cash price runs $150 to $300 or more per month depending on the pharmacy and region. There is no meaningful clinical advantage to the brand formulation for most patients.

Cost Comparison Across Osteoporosis Drug Classes

The cost difference between bisphosphonates and the alternatives is dramatic, and this is directly relevant when an insurer requires step therapy through an approved male agent first.

| Drug | Route | Frequency | Approximate Monthly Cost (Generic/Cash) | |---|---|---|---| | Alendronate 70 mg | Oral | Weekly | $4, $15 | | Risedronate 35 mg | Oral | Weekly | $15, $40 | | Zoledronic acid 5 mg | IV infusion | Yearly | $200, $1,200 per infusion (facility-dependent) | | Denosumab (Prolia) | Subcutaneous injection | Every 6 months | $1,100, $1,400 per injection without insurance | | Teriparatide (Forteo) | Subcutaneous injection daily | Daily | $3,000, $5,000/month |

The table makes clear why generic alendronate is almost always tried first, whether in women or men. The cost argument for alendronate is not close.

Manufacturer and Assistance Programs

Because generic alendronate is already cheap, manufacturer patient-assistance programs are essentially nonexistent for this drug. The better strategy is to use a GoodRx, RxSaver, or NeedyMeds coupon at a discount pharmacy chain. For patients with income below 200 percent of the federal poverty level, NeedyMeds (needymeds.org) maintains a list of state pharmaceutical assistance programs that may cover generic drugs not covered by insurance.

What the Clinical Evidence Actually Shows in Men

This section matters because the insurance fight often hinges on whether the evidence in men is strong enough to justify off-label coverage. Here is an honest read of the data.

Trials Conducted in Men

The most frequently cited study is the Orwoll et al. (2000) randomized controlled trial published in the New England Journal of Medicine. That trial enrolled 241 men with osteoporosis and randomized them to alendronate 10 mg daily or placebo for two years. Men receiving alendronate had a 7.1 percent increase in lumbar spine BMD compared with a 0.6 percent increase in the placebo group. Vertebral fracture incidence was lower in the alendronate group, though the trial was underpowered to show a statistically significant fracture reduction in isolation.

The subsequent Orwoll et al. Extension study confirmed BMD gains were maintained at three years.

A Cochrane systematic review on bisphosphonates for osteoporosis in men found that bisphosphonates, including alendronate, significantly increased BMD at the lumbar spine and femoral neck compared with placebo in men, and were associated with a reduction in vertebral fracture risk. The authors noted that the evidence base was smaller than for postmenopausal women, a point worth acknowledging honestly.

The Evidence-Gap Caveat (W6)

Women have historically made up the majority of participants in osteoporosis trials. The landmark Fracture Intervention Trial (FIT), which established alendronate's fracture-reduction benefits and directly informed its FDA approval, enrolled only postmenopausal women. What we know about male fracture reduction with alendronate is extrapolated in part from that female data and from the smaller male-specific trials above. That is not a reason to withhold treatment from men with documented osteoporosis, but it is a reason to be transparent with your prescriber and your insurer about what the evidence does and does not directly show.

How Bone Loss Differs Between Men and Women Across Life Stages

Understanding the sex-specific physiology here helps you frame the conversation with an insurer or a clinician.

Reproductive Years and Perimenopause (Women)

In women, bone mass peaks around age 25 to 30. Estrogen is the primary regulator of bone resorption. As estrogen declines during perimenopause, bone turnover accelerates sharply. Women can lose 2 to 3 percent of bone mass per year in the first five years after menopause, according to data from the Study of Women's Health Across the Nation (SWAN). This is why alendronate's FDA approval for postmenopausal osteoporosis was studied and approved specifically in this population.

Men and Age-Related Bone Loss

Men do not experience a sudden hormonal transition comparable to menopause. Instead, testosterone and estradiol (yes, estradiol, because men convert testosterone to estradiol via aromatase, and estradiol governs bone resorption in men too) decline gradually. Significant bone loss in men typically accelerates after age 65 to 70. Men with hypogonadism, whether from primary testicular failure, pituitary disease, or androgen deprivation therapy for prostate cancer, lose bone rapidly at any age. Androgen deprivation therapy is associated with a 2 to 8 percent annual BMD loss in men with prostate cancer. In that population, bisphosphonate use in men is substantially better supported.

PCOS, Perimenopause, and Bone Health in Women (W5)

Women with polycystic ovary syndrome (PCOS) who are anovulatory have lower progesterone exposure and may have altered bone turnover, though the net effect on fracture risk is still debated. Women in perimenopause with irregular cycles have episodic estrogen withdrawal that can accelerate bone loss before they would even qualify for a postmenopausal diagnosis. This is why DXA screening discussions for women with PCOS or early perimenopause deserve individualized attention, separate from the standard screening age of 65 for all women.

Pregnancy, Lactation, and Contraception (Required for All Drug Articles)

Alendronate is contraindicated in pregnancy. This is not a nuanced clinical gray area.

Bisphosphonates incorporate into bone and have a very long skeletal half-life, estimated at more than 10 years in humans. Animal studies show fetal skeletal abnormalities and reduced birth weight with bisphosphonate exposure. Although human data on inadvertent first-trimester exposure is limited and does not yet show a clear pattern of teratogenicity, the FDA classifies alendronate as Pregnancy Category D (under the legacy system), meaning there is positive evidence of human fetal risk or sufficient animal evidence combined with long skeletal retention to warrant contraindication.

If you are a woman of reproductive age who is prescribed alendronate for premature bone loss (a situation that does arise in women with glucocorticoid-dependent conditions such as lupus or inflammatory bowel disease, or after bilateral oophorectomy), you must use reliable contraception while taking alendronate and should discuss the long washout period with your prescriber before attempting conception. Stopping alendronate even 12 months before conception does not guarantee the drug has cleared bone stores. There is no established safe interval.

Lactation: Alendronate transfer into human breast milk has not been studied. Given the drug's mechanism and skeletal retention, breastfeeding is not recommended during treatment. If you are postpartum and were taking alendronate before pregnancy, discuss timing of resumption with your clinician. Many providers delay restarting until breastfeeding has ended.

For the male partner context: If your male partner takes alendronate, there is no known risk to a female partner's pregnancy through sperm exposure. The drug does not appear in semen at clinically meaningful concentrations.

Who This Drug Is Right For, and Who It Is Not

Right for:

• Men age 50 or older with a DXA T-score at or below -2.5 at the spine, hip, or femoral neck.
• Men with osteopenia (T-score -1.0 to -2.5) plus a 10-year FRAX fracture probability at or above 20 percent for major osteoporotic fracture or 3 percent for hip fracture, per the National Osteoporosis Foundation guidelines.
• Men on long-term glucocorticoid therapy (prednisone 7.5 mg per day or more for three or more months). In this case, alendronate has FDA approval regardless of sex.
• Men on androgen deprivation therapy for prostate cancer with confirmed bone loss.
• Women of any age with postmenopausal osteoporosis or glucocorticoid-induced bone loss (on-label).
• Women in perimenopause with documented bone loss and contraindications to hormone therapy.

Not right for:

• Women who are pregnant or planning pregnancy within the next several years without a detailed risk-benefit discussion.
• Women who are breastfeeding.
• Anyone with esophageal abnormalities (stricture, achalasia) or an inability to sit upright for 30 minutes after taking the pill.
• Patients with an estimated GFR below 35 mL/min per 1.73 m squared. Alendronate is not recommended in severe renal impairment.
• Patients with hypocalcemia. Correct calcium deficiency before starting any bisphosphonate.

Navigating the Prior Authorization and Appeal Process

The WomanRx Prior Auth Framework for Off-Label Bisphosphonate Coverage in Men gives you a practical path when a claim is first denied.

Step 1. Document the DXA with T-scores at multiple sites. A single spine measurement is not enough. Request hip and femoral neck T-scores in the DXA report. Insurers look for at least one site at -2.5 or below.

Step 2. Rule out or document secondary causes. Labs your prescriber should order: serum calcium, phosphorus, 25-hydroxyvitamin D, testosterone (total and free), TSH, complete metabolic panel, and a 24-hour urine calcium. Hypogonadism documented in the chart strengthens the case because androgen deficiency-related osteoporosis in men is a well-documented secondary cause, and bisphosphonates in that context have strong guideline support.

Step 3. Cite the Endocrine Society guideline explicitly in the appeal letter. The 2012 Endocrine Society Clinical Practice Guideline on Osteoporosis in Men states: "We recommend treatment with a bisphosphonate (alendronate, risedronate, or zoledronic acid) in men with osteoporosis." That direct guideline language belongs in every appeal letter.

Step 4. Request a peer-to-peer review. When a prior authorization is denied, your prescriber has the right to speak directly with the insurer's medical reviewer. This step alone reverses denials in a meaningful proportion of cases.

Step 5. If all else fails, use the coupon. Generic alendronate at $4 to $15 per month is affordable for most patients even without coverage. The cost argument for fighting a denial hard diminishes when the out-of-pocket cost is already this low. Spend political capital on the more expensive drugs first.

Frequently Asked Questions